OnKure Therapeutics, Inc. (OKUR) 10-Year Financial Performance & Capital Metrics

OKUR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutOnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.Show more

Revenue $0
EBITDA -$54M -47.7%
Net Income -$53M -49.2%
EPS (Diluted) -3.95 -49.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -5304.43%
ROIC -
Debt/Equity 0.01
Interest Coverage -181.29

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.4x book value

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-818.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM-653.03%

ROCE

10Y Avg-77.62%

5Y Avg-77.62%

3Y Avg-103.12%

Latest-81.89%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	37K	50K	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-37K	-50K	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-0.35%	1%	-	-
Operating Expenses+	19.52M	39.77M	29.77M	36.93M	54.39M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	3.61M	11.65M	3.9M	4.82M	10.59M
SG&A % of Revenue	-	-	-	-	-
Research & Development	15.91M	28.12M	25.86M	32.12M	43.8M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-19.55M	-39.82M	-29.77M	-36.93M	-54.39M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-1.04%	0.25%	-0.24%	-0.47%
EBITDA+	-19.52M	-39.77M	-29.38M	-36.37M	-53.72M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-1.04%	0.26%	-0.24%	-0.48%
D&A (Non-Cash Add-back)	37K	50K	387K	560K	662K
EBIT	-19.46M	-39.77M	-29.77M	-35.31M	-52.37M
Net Interest Income+	0	0	254K	1.62M	1.71M
Interest Income	0	0	254K	1.62M	2.01M
Interest Expense	0	0	0	0	300K
Other Income/Expense	87K	48K	254K	1.62M	1.71M
Pretax Income+	-19.46M	-39.77M	-29.51M	-35.31M	-52.67M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-19.46M	-39.77M	-29.51M	-35.31M	-52.67M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.04%	0.26%	-0.2%	-0.49%
Net Income (Continuing)	-19.46M	-39.77M	-29.51M	-35.31M	-52.67M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-7.74	-21.92	-2.21	-2.65	-3.95
EPS Growth %	-	-1.83%	0.9%	-0.2%	-0.49%
EPS (Basic)	-7.74	-21.92	-2.21	-2.65	-3.95
Diluted Shares Outstanding	2.51M	1.81M	13.34M	13.34M	13.34M
Basic Shares Outstanding	2.51M	1.81M	13.34M	13.34M	13.34M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	55.02M	153.73M	13.62M	33.77M	113M
Cash & Short-Term Investments	53.61M	147.67M	11.54M	29.88M	110.76M
Cash Only	53.61M	124.66M	11.54M	29.88M	110.76M
Short-Term Investments	0	23.01M	0	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	1.41M	6.06M	840K	0	0
Total Non-Current Assets+	196K	290K	2.38M	1.97M	1.9M
Property, Plant & Equipment	69K	212K	2.05M	1.91M	1.79M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	127K	78K	329K	58K	109K
Total Assets+	55.22M	154.02M	16M	35.73M	114.91M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	1.79%	-0.9%	1.23%	2.22%
Total Current Liabilities+	4.58M	6.2M	5.54M	7.29M	10.53M
Accounts Payable	0	0	2.52M	3.42M	2.97M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	4.58M	6.2M	1.46M	1.66M	3.17M
Current Ratio	12.01x	24.79x	2.46x	4.64x	10.73x
Quick Ratio	12.01x	24.79x	2.46x	4.64x	10.73x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	92.76M	611K	64.88M	130.29M	549K
Long-Term Debt	92.72M	0	0	0	0
Capital Lease Obligations	0	0	486K	466K	549K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	444K	64.39M	129.82M	0
Total Liabilities	97.34M	6.81M	70.42M	137.58M	11.08M
Total Debt+	92.72M	0	637K	674K	1.08M
Net Debt	39.11M	-124.66M	-10.91M	-29.2M	-109.68M
Debt / Equity	-	-	-	-	0.01x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-181.29x
Total Equity+	-42.12M	147.21M	-54.42M	-101.84M	103.83M
Equity Growth %	-	4.5%	-1.37%	-0.87%	2.02%
Book Value per Share	-16.75	81.14	-4.08	-7.63	7.78
Total Shareholders' Equity	-42.12M	147.21M	-54.42M	-101.84M	103.83M
Common Stock	1K	3K	1K	0	1K
Retained Earnings	-44.96M	-84.73M	-57.07M	-102.05M	-154.72M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	34K	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.54M	-37.98M	-26.95M	-34.55M	-51.12M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-1.05%	0.29%	-0.28%	-0.48%
Net Income	-19.46M	-39.77M	-29.51M	-35.31M	-52.67M
Depreciation & Amortization	37K	50K	387K	560K	662K
Stock-Based Compensation	0	0	48K	199K	4.53M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	378K	4.54M	0	0	316K
Working Capital Changes	514K	-2.8M	2.12M	6K	-3.95M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	1.71M	-5.93M
Cash from Investing+	7.38M	-23.38M	-1.13M	-246K	15.87M
Capital Expenditures	-24K	-198K	-1.13M	-246K	-52K
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	-44.1M	0	0
Cash from Financing+	47.27M	132.41M	26.46M	53.13M	116.13M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	-1.38M	-723K	51.22M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-18.56M	-38.18M	-28.09M	-34.79M	-51.17M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-1.06%	0.26%	-0.24%	-0.47%
FCF per Share	-7.38	-21.04	-2.11	-2.61	-3.84
FCF Conversion (FCF/Net Income)	0.95x	0.96x	0.91x	0.98x	0.97x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-75.68%	-63.61%	-	-5304.43%
Return on Invested Capital (ROIC)	-	-305.62%	-	-	-
Debt / Equity	-	-	-	-	0.01x
Interest Coverage	-	-	-	-	-181.29x
FCF Conversion	0.95x	0.96x	0.91x	0.98x	0.97x

Frequently Asked Questions

Growth & Financials

OnKure Therapeutics, Inc. (OKUR) grew revenue by 0.0% over the past year. Growth has been modest.

OnKure Therapeutics, Inc. (OKUR) reported a net loss of $81.2M for fiscal year 2024.

Dividend & Returns

OnKure Therapeutics, Inc. (OKUR) has a return on equity (ROE) of -5304.4%. Negative ROE indicates the company is unprofitable.

OnKure Therapeutics, Inc. (OKUR) had negative free cash flow of $61.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener